ReTHINK: A Phase 3 Study of Ruxolitinib in Early Myelofibrosis Patients
Автор: MPNUniversity .tv
Загружено: 2017-07-25
Просмотров: 122
Описание:
Hi. My name is Alessandro Vannucchi, and I'm an associate professor of hematology at the University of Florence. The topic of this short presentation is about the ReTHINK study; that is a phase 3 study of ruxolitinib in early myelofibrosis patients.
We know that myelofibrosis is a progressive disease. Indeed, if you compare patients at diagnosis with those seen after 1 year of diagnosis, the proportion of patients who have anemia, thrombocytopenia, circulating blasts, need of transfusions, constitutional symptoms, and splenomegaly, is definitely higher just 1 year after the diagnosis, according with to data from the Mayo Clinic.
We also know from the data obtained in the perspective COMFORT trials—and this slide actually is showing results from COMFORT I—that patients who received placebo in this study experienced an increased symptomatic burden over the course of the study.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
